The worldwide market for in vitro diagnostic (ivd) tests, 8th edition
The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 8thEditionThis year, Kalorama has published its eighth edition of this informative volume based on themarket events of 2011. The report is over 1400 pages, reflecting the dramatic change inIVD. New entrants, net technologies have entered the stage and all important events arecataloged in this report. The idea behind Kaloramas unique report is that the entire market canbe captured in one volume and business planners avoid multiple purchases. Published every twoyears, this volume includes coverage of the most important aspects of all of the major segmentsof clinical lab testing, including: Point of Care (POC), (Professional and Self-Testing) Histology and Cytology (Pap, ISH, IHC, traditional non-pap, HPV) Core Lab (General Chemistries, Workstations, Analyzers) Immunoassays (Blood Gases, Urinalysis, Critical Care) Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal) Hematology Coagulation (Lab-Based, POC, Genetic Markers) Microbiology and Virology Blood Banking (Grouping, Immunoassay Screens, NAT Screens)Market sizes, forecasts and shares are provided, as well as a geographic breakdown of thesegments, where possible. Changes in technology development, regulatory and reimbursementissues, clinical care, and business environments are discussed. Current market numbers arepresented for 2011, with projections given through 2016.The "Bible of the IVD Industry"Now in 8 editions, this report has become the go-to market research reference for theindustry. Many of the top IVD companies use this product for business planning, which meansthat this volume can provide a uniform standard for in vitro diagnostic market numbers. Thisedition greatly expands coverage of the field and tracks the most important developments. Seeaspects of the industry that might not be available in your companys internal resources. Viewthe market from an independent point of view. Learn about competitors in away that may beinvisible to internal personnel. Know the market players - your competitors and potentialpartners, in proper context and classification. Save countless hours of staff time and otherresearch expenses with the authoritative guide for IVD market estimates and forecasts.A Global ReportFrom the first edition, this report was designed as a global resource in order to give market-
watchers a true picture of the industry. IVD is a worldwide business. While the US is a largehealthcare market, much of the dynamism, the growth, and also competition is occurring in otherareas. Many of the most interesting opportunities for companies are occurring in emergingmarkets. As part of its coverage, the report breaks down the entire IVD market for the followingregions. North America Europe (EU countries, incl. IVD market sizes by country) Eastern Europe South America Asia (Japan, China and India) Rest of WorldA Report Designed for a Changing IndustryA number of totally disparate phenomena have come together to change the IVD industry.Human genome research is finding links between a person’s genome and several lifestylesituations such as nutrition, dieting, skin conditions and other essentially non-medical conditions.This has attracted consumer product companies such as Proctor & Gamble and Nestlé to developproducts and services based on IVD technologies. Decreases in life science grants hasencouraged companies active in this space to migrate their technologies for clinical applications. The result is the entry of companies such as Caliper Life Sciences, Illumina, Affymetrix andLife Technologies to the diagnostics market with products and test services. Miniaturization oftraditional immunoassay and molecular test technologies has finally matured to the point wherethey may be ready for scale-up and then commercialization into products. Here electronicscompanies such as Sony, Samsung, Dell Computers and Intel Corp. have invested in clinicaldiagnostics ventures. These exciting developments join expansion into new market segments bycompanies already involved in the IVD industry.In 2010 and 2011, there were at least 74 acquisitions and some 36 distribution agreements. Andthis is only a small portion of what is really happening. There are many more deals that have notbeen announced. The goal is to build better tests and stronger companies. The future of theindustry lies in the development of more sensitive, faster, user-friendly, IT capable devices for ahost of new protein and molecular markers.In this eighth edition of The Worldwide Market for In Vitro Diagnostic Tests KaloramaInformation addresses all of the key issues affecting the diagnostic industry in 2012 and howcompetitors are faring. Among the topics tackled in this report:Molecular diagnostics including infectious disease mdx, pharmacodiagnostics, molecular pocand test services are put in a context.
Merging IT and IVD: Establishing the EMR Record from IVD Tests Healthcare Reform and its Possible Impact on IVD. The Status of Automation in the Lab; Core Lab Section Includes Both Workstation and Automated Panel Revenues. Mass Spec, Next Gen Sequencing and Other Technology Entrants Hospital Infection Testing - the latest Several Hundred Company profiles. Top tier companies, Second and Third Tier companies but also Smaller Innovators. The report‘s profiles distinguish between companies that are leaders in all aspects of IVD, those that are Specialists in one particular area or a few. Major Mergers as well as Partnerships, Distribution Agreements. Brazil, India and China - Important Emerging Markets for IVD. Innovations in Blood Banking Histology/Cytology innovations; the role of FISH testing and Digital Images Healthcare statistics for various countries -healthcare spending as a percent of GDP, new hospitals, cost increases and other information. Tables that document the most competitive products on the market and under development in each area of IVD. Country-level Breakout of IVD market for major European and Asian countries. The Current Economic Situation Update on the Regulation of Novel DevicesBuy your copy of this report @ http://www.reportsnreports.com/reports/183811-the-worldwide-market-for-in-vitro-diagnostic-ivd-tests-8th-edition.htmlReport Details:Published: July 2012No. of Pages: 1400Price : Single User License: US$ 6500 Price : Corporate User License: US$ 13000Table of contentsCHAPTER ONE: EXECUTIVE SUMMARYIntroduction – Doing more with lessScope and MethodologySize and Growth of the MarketMarket TrendsCHAPTER TWO: INTRODUCTIONBackgroundReport DesignLab Medicine Disciplines And Applications
Market Analysis of IVD Market SegmentsThe lure of IVD – new majors and entrantsLicenses and distribution agreementsTest ServicesTop Suppliers and Niche playersPoint of ViewCHAPTER THREE: OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC MARKETSBackgroundPopulation and Disease Demographics, WorldwideChronic Diseases as a Market DriverCancerDiabetesAllergyThe BRIC EffectWorld Segments of the IVD Market and IVD Market EvolutionSpecific Country InformationThe United States of America – a world in fluxRUO/IUO IssuesThe Patient Protection and Affordable Care ActAccountable Care OrganizationsLDT OversightAccent on Preventative CareIn Patient BundlingMolecular test reimbursementJapanEurope – effects of austerityIVD Directive UpdateChinaIndiaBrazilRussiaCHAPTER FOUR: TRENDS AND INNOVATIONBackgroundLooking to the EastLooking Past the Hospital ERTelemedicine and Home Care TrendsCommercialization of Novel TestsEMR UpdateWireless Connectivity and Healthcare EfficienciesApps everywhereThe search for non-invasive toolsCHAPTER FIVE: POINT-OF-CARE TEST PLATFORMSOverview of POC Tests
The Major POC Test PlayersMarket AnalysisBlood Glucose MonitoringBlood Glucose Self TestingContinuous Self TestingBlood Glucose Testing by ProfessionalsDiabetes Testing – Glycated HemoglobinThe Genetics of DiabetesThe Commercial Outlook for POC TestsCHAPTER SIX: THE CORE LABCore Lab OverviewOverview of Chemistry TestsMarket Analysis : Leading Suppliers and Growth PotentialLab-based ChemistriesCritical Care AnalysisUrinalysisThe Commercial Outlook for the Core LabCHAPTER SEVEN: IMMUNOASSAYSOverview of ImmunoassaysMarket AnalysisImmunoassay Test Segments - Mature and EmergingPoint-of-care OTC and Professional UseThe Commercial Outlook for ImmunoassaysCHAPTER EIGHT: MOLECULAR ASSAY PLATFORMSOverview of Molecular AssaysWorldwide Opportunities for Molecular TestsMolecular Test User MarketsNext generation SequencingMass SpectroscopyMolecular Technologies And PlayersMarket AnalysisOncologyInherited DiseasesPharmacodiagnosticsPrenatal Chromosome AnalysisTissue TypingThe Commercial Outlook for Molecular TestsCHAPTER NINE: HEMATOLOGYOverview of HematologyAutomation and ITDigital EvolutionDecentralized Hematology Testing
Market Analysis : Leading SuppliersThe Commercial Outlook for Hematology TestsCHAPTER TEN: COAGULATIONOverview of Coagulation / Immunohematology TestsSpecial TopicGenetics and Personalized MedicineWarfarinPlavixMarket AnalysisLab-based TestingGenetic markers of hypercoagulopathiesDecentralized Coagulation testing – Professional UseDecentralized Coagulation testing – OTCPlatelet TestingLeading SuppliersThe Commercial Outlook for Coagulation TestsCHAPTER ELEVEN: MICROBIOLOGY AND VIROLOGYOverview of Microbiology / Virology TestsSpecial TopicsAntimicrobial Drug ResistanceGenome Sequencing and Mass SpectrometrySepsis SerologyMarket AnalysisSuppliesChromogenic MediaMicrobial Identification and Antimicrobial Sensitivity TestsLiquid MicrobiologyBlood CultureImmunoassays – lab basedImmunoassays – rapidMolecular TestsThe Commercial Outlook for Microbiology / Virology TestsCHAPTER TWELVE: BLOOD BANKING SERVICESOverview of Blood BankingBlood Management – are all these transfusions good medicineBlood TrackingChagas DiseasePlatelet SafetyMarket AnalysisBlood GroupingImmunoassay ScreensNucleic Acid Testing Continues to GrowLeading Suppliers
The Commercial Outlook for Blood BankingCHAPTER THIRTEEN: HISTOLOGY AND CYTOLOGYOverview of Histology / CytologySpecial TopicsCompanies expand with test servicesMarket AnalysisHistology/CytologyTraditional StainsPap and HPV TestsImmunochemistry and In Situ HybridizationPharmacodiagnostic HistologyDigital ImagingTissue MicroarraysCirculating Tumor CellsChromosome AnalysisFlow CytometryThe Commercial Outlook for Histology and Cytology TestsCOMPANIES PROFILEDCHAPTER FOURTEEN: The Top TierAbbott DiagnosticsAlereArkrayBeckman Coulter Inc.Becton, Dickinson and Company (BD)bioMérieux Inc.Bio-Rad Laboratories Inc.Danaher CorporationGen-Probe Inc.Hologic, Inc.Horiba MedicalInstrumentation Laboratory (IL)Ortho Clinical DiagnosticsQIAGEN N.V.Radiometer A/SRoche DiagnosticsSiemens Healthcare DiagnosticsSysmex CorporationThermo Fisher Scientific Inc.CHAPTER FIFTEEN: The Second TierAffymetrix, Inc.Agilent Technologies Inc.Axis-Shield plc
Bruker BioSciences CorporationCelera DiagnosticsCepheidChina Medical TechnologiesDako A/SDiaSorin S.p.A.Eiken Chemical Co., LtdELITech GroupFujirebio Diagnostics, Inc.General Electric - GE HealthcareGrifols, S.A.Illumina Inc.IRIS International, Inc.Life TechnologiesLuminex CorporationMagellan BiosciencesA. Menarini DiagnosticsMindray Bio-Medical Electronics Co., LtdNanosphere, Inc.Nova BiomedicalNovartis DiagnosticsPerkinElmer, Inc.Phadia ABQuidel CorporationRandox Laboratories Ltd.SequenomTosoh CorporationTransasia Bio-Medicals Ltd.Trinity Biotech plcVentana Medical Systems Inc.Veridex, LLCWako Pure Chemical Industries, Ltd.Werfen Group S.AContact: email@example.com for further details.